Skip to main content
Premium Trial:

Request an Annual Quote

Carl March, Jack Singer, Fred Telling, James Bianco

Premium
Cell Therapeutics this week announced the management team for its recently-formed subsidiary Aequus BioPharma. Carl March has been chosen as president and CEO. Stewart Chipman will serve as executive vice president and CSO. David Cosman will join the company's board of directors.
 
Additional board members will include Jack Singer, Fred Telling, and James Bianco, who will serve as non-executive chairman.
 
March was previously senior vice president of information technology and biochemical sciences at Immunex. Chipman, currently the vice president of research at CTI, was previously Immunex’ director of biomolecular screening. Cosman, currently vice president of molecular biology at Immunex, was previously distinguished fellow and research director at Amgen.
 
CTI also announced this week that it will co-develop AQB-101 with Aequus BioPharma. AQB-101 is being developed as a follow-on biologic to help fight infection in some patients taking chemotherapy. AQB-101 is a genetic polymer-modified version of G-CSF.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.